Previous Close | 21.97 |
Open | 22.11 |
Bid | 21.84 x 100 |
Ask | 21.89 x 100 |
Day's Range | 21.50 - 22.33 |
52 Week Range | 11.22 - 25.34 |
Volume | |
Avg. Volume | 1,094,893 |
Market Cap | 1.858B |
Beta (5Y Monthly) | 0.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]